Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): a randomised, double-blinded, multicentre, phase 2 study
European Respiratory Journal · 2026-07 · 68 (1) · 2501874
DOI: 10.1183/13993003.01874-2025 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Respiratory Journal, online erschienen am 12.03.2026. Verfasst von Bernt Van Den Blink und 16 weiteren Autor:innen. Beteiligte Einrichtung: Kinevant Sciences, Inc., New York, NY, USA. Hauptthemen laut MEDLINE: Sarcoidosis, Pulmonary, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Treatment options for chronic pulmonary sarcoidosis are limited in efficacy and by tolerability concerns. Namilumab, an investigational humanised monoclonal antibody inhibiting granulocyte–macrophage colony-stimulating factor, was hypothesised to downregulate the granulomatous response in pulmonary sarcoidosis.
Methods
RESOLVE-Lung was a double-blind, placebo-controlled trial in participants with chronic active pulmonary sarcoidosis on oral corticosteroids (OCS) and/or immunosuppressive therapies (IST). Participants were randomised (1:1) to receive 150 mg namilumab or placebo via subcutaneous injection every 4 weeks and were required to stop IST and/or taper OCS. End-points were assessed at week 26. The primary end-point was the proportion of participants with a rescue event, such as disease worsening necessitating treatment. Secondary end-points included safety, lung function assessments and corticosteroid burden. The trial was registered at ClinicalTrials.gov ( NCT05314517 ).
Results
Of 209 participants screened, 107 were randomised to receive namilumab (n=53) or placebo (n=54). The proportion of participants with a rescue event was higher for the namilumab group (37.5%) compared with the placebo group (23.5%) (stratified difference 13.6 (90% CI −1.5–28.7) percentage points; p=0.12). The least squares (LS) mean change from baseline in forced vital capacity % predicted was −3.3 (90% CI −5.1– −1.5) percentage points for namilumab and −2.9 (90% CI −4.5– −1.3) percentage points for placebo (LS mean difference −0.4 (90% CI −2.7–2.0) percentage points). The proportion of participants successfully achieving OCS taper was 53.3% for namilumab and 76.9% for placebo (difference −19.4 (90% CI −47.5–8.7) percentage points). Treatment-emergent adverse events were reported in 94% in both groups, most being mild or moderate in severity.
Conclusion
In participants with chronic active pulmonary sarcoidosis, namilumab did not provide clinical benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Kinevant Sciences, Inc., New York, NY, USA.
- Centre for Human and Applied Physiological Sciences, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.
- Department of Chest Diseases, University of Ege, Izmir, Turkey.
- Department of Pulmonology, University of Mersin, Mersin, Turkey.
- Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
- Department of Respiratory Medicine, CHU Liège, Liège, Belgium.
ORCID-Profile: Simon P Hart, Hajira B Koeller
Zitieren
APA
Van Den Blink, B., Birring, S. S., Mogulkoc, N., Nayci Atis, S., Gupta, R., Guiot, J., Hart, S. P., Carmona Porquera, E. M., Koeller, H. B., Arocho, N., Petit, C. M., Denning, J., Lin, M., Baughman, R. P., Wijsenbeek-Lourens, M., Reiss, T. F., & RESOLVE-Lung investigators (2026). Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): a randomised, double-blinded, multicentre, phase 2 study. European Respiratory Journal, 68(1), 2501874. https://doi.org/10.1183/13993003.01874-2025
Vancouver
Van Den Blink B, Birring SS, Mogulkoc N, Nayci Atis S, Gupta R, Guiot J, et al. Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): a randomised, double-blinded, multicentre, phase 2 study. European Respiratory Journal. 2026;68(1):2501874. doi:10.1183/13993003.01874-2025
BibTeX
@article{VanDenBlink2026,
author = {Van Den Blink, Bernt and Birring, Surinder S and Mogulkoc, Nesrin and Nayci Atis, Sibel and Gupta, Rohit and Guiot, Julien and Hart, Simon P and Carmona Porquera, Eva M and Koeller, Hajira B and Arocho, Natasha and Petit, Chantal M and Denning, Jill and Lin, Min and Baughman, Robert P and Wijsenbeek-Lourens, Marlies and Reiss, Theodore F and RESOLVE-Lung investigators, RESOLVE-Lung investigators},
title = {Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): a randomised, double-blinded, multicentre, phase 2 study},
journal = {European Respiratory Journal},
year = {2026},
volume = {68},
number = {1},
pages = {2501874},
doi = {10.1183/13993003.01874-2025}
}
EUVIMED